305 related articles for article (PubMed ID: 33959771)
1. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
Yonezawa H; Ohno M; Igaki H; Miyakita Y; Takahashi M; Tamura Y; Shima S; Matsushita Y; Ichimura K; Narita Y
Jpn J Clin Oncol; 2021 Jul; 51(7):1028-1035. PubMed ID: 33959771
[TBL] [Abstract][Full Text] [Related]
2. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
Shi W; Blomain ES; Siglin J; Palmer JD; Dan T; Wang Y; Werner-Wasik M; Glass J; Kim L; Bar Ad V; Bhamidipati D; Evans JJ; Judy K; Farrell CJ; Andrews DW
J Neurooncol; 2018 Mar; 137(1):171-177. PubMed ID: 29235052
[TBL] [Abstract][Full Text] [Related]
3. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas.
Hundsberger T; Brügge D; Putora PM; Weder P; Weber J; Plasswilm L
J Neurooncol; 2013 Mar; 112(1):133-9. PubMed ID: 23314822
[TBL] [Abstract][Full Text] [Related]
4. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G
Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134
[TBL] [Abstract][Full Text] [Related]
5. High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?
Gupta T; Maitre M; Maitre P; Goda JS; Krishnatry R; Chatterjee A; Moiyadi A; Shetty P; Epari S; Sahay A; Patil V; Jalali R
Clin Transl Oncol; 2021 Jul; 23(7):1358-1367. PubMed ID: 33528810
[TBL] [Abstract][Full Text] [Related]
6. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.
Arvold ND; Shi DD; Aizer AA; Norden AD; Reardon DA; Lee EQ; Nayak L; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Wen PY; Alexander BM
J Neurooncol; 2017 Dec; 135(3):581-591. PubMed ID: 28975467
[TBL] [Abstract][Full Text] [Related]
7. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
[TBL] [Abstract][Full Text] [Related]
10. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.
Dixit KS; Sachdev S; Amidei C; Kumthekar P; Kruser TJ; Gondi V; Grimm S; Lukas RV; Nicholas MK; Chmura SJ; Fought AJ; Mehta M; Raizer JJ
J Neurooncol; 2021 Dec; 155(3):297-306. PubMed ID: 34689306
[TBL] [Abstract][Full Text] [Related]
11. Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.
Schnell O; Thorsteinsdottir J; Fleischmann DF; Lenski M; Abenhardt W; Giese A; Tonn JC; Belka C; Kreth FW; Niyazi M
J Neurooncol; 2016 Dec; 130(3):591-599. PubMed ID: 27599828
[TBL] [Abstract][Full Text] [Related]
12.
Fleischmann DF; Unterrainer M; Bartenstein P; Belka C; Albert NL; Niyazi M
J Neurooncol; 2017 Apr; 132(2):277-286. PubMed ID: 28102485
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients.
Detti B; Scoccianti S; Teriaca MA; Maragna V; Lorenzetti V; Lucidi S; Bellini C; Greto D; Desideri I; Livi L
Radiol Med; 2021 Sep; 126(9):1249-1254. PubMed ID: 34081269
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M
J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747
[TBL] [Abstract][Full Text] [Related]
15. Re-Irradiation for Recurrent Gliomas: Treatment Outcomes and Prognostic Factors.
Lee J; Cho J; Chang JH; Suh CO
Yonsei Med J; 2016 Jul; 57(4):824-30. PubMed ID: 27189273
[TBL] [Abstract][Full Text] [Related]
16. Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma.
Combs SE; Edler L; Rausch R; Welzel T; Wick W; Debus J
Acta Oncol; 2013 Jan; 52(1):147-52. PubMed ID: 22686472
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
Gutin PH; Iwamoto FM; Beal K; Mohile NA; Karimi S; Hou BL; Lymberis S; Yamada Y; Chang J; Abrey LE
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):156-63. PubMed ID: 19167838
[TBL] [Abstract][Full Text] [Related]
18. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
Gorsi HS; Khanna PC; Tumblin M; Yeh-Nayre L; Milburn M; Elster JD; Crawford JR
Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
[TBL] [Abstract][Full Text] [Related]
19. Timing of re-irradiation in recurrent high-grade gliomas: a single institution study.
Zemlin A; Märtens B; Wiese B; Merten R; Steinmann D
J Neurooncol; 2018 Jul; 138(3):571-579. PubMed ID: 29520609
[TBL] [Abstract][Full Text] [Related]
20. The role of salvage reirradiation for malignant gliomas that progress on bevacizumab.
Torcuator RG; Thind R; Patel M; Mohan YS; Anderson J; Doyle T; Ryu S; Jain R; Schultz L; Rosenblum M; Mikkelsen T
J Neurooncol; 2010 May; 97(3):401-7. PubMed ID: 19838627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
